AS04-adjuvanted virus-like particles containing multiple M2 extracellular domains of influenza virus confer improved protection

Vaccine

Volumn 32, Issue 35, 2014, Pages 4578-4585

  Lee, Yu Na ^a   Kim, Min Chul ^a,b   Lee, Young Tae ^a   Hwang, Hye Suk ^a   Cho, Min Kyoung ^a   Lee, Jong Seok ^a   Ko, Eun Ju ^a   Kwon, Young Man ^a   Kang, Sang Moo ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b Animal Plant and Fisheries Quarantine and Inspection Agency   (South Korea)

Author keywords

Adjuvants; C57BL 6; Influenza virus; M2e VLPs

Indexed keywords

3 O DESACYL 4' MONOPHOSPHORYL LIPID A; ALUMINUM POTASSIUM SULFATE; AS04; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; M2EVLP VACCINE; PHOSPHORYL LIPID A; PROTEIN M2; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; ALUMINUM HYDROXIDE; ASO4 MIXTURE; LIPID A; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACULOVIRUS; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PROTECTION; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; VACCINATION; VIRUS LIKE AGENT; VIRUS STRAIN; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; C57BL MOUSE; DISEASE MODEL; GENETICS; IMMUNOLOGY; ORTHOMYXOVIRIDAE INFECTIONS; SECRETION (PROCESS);

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FEMALE; INFLUENZA VACCINES; INTERFERON-GAMMA; LIPID A; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, VIRUS-LIKE PARTICLE; VIRAL MATRIX PROTEINS;

EID: 84904397430     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.06.040     Document Type: Article

References (36)

1. Ito T., Gorman O.T., Kawaoka Y., Bean W.J., Webster R.G. Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J Virol 1991, 65:5491-5498.
2. Zebedee S.L., Lamb R.A. Nucleotide sequences of influenza A virus RNA segment 7: a comparison of five isolates. Nucleic Acids Res 1989, 17:2870.
3. Fiers W., De Filette M., Birkett A., Neirynck S., Min Jou W. A "universal" human influenza A vaccine. Virus Res 2004, 103:173-176.
4. Du L., Zhou Y., Jiang S. Research and development of universal influenza vaccines. Microbes Infect 2010, 12:280-286.
5. Zhao G., Lin Y., Du L., Guan J., Sun S., Sui H., et al. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol J 2010, 7:9.
6. Wang B.Z., Gill H.S., Kang S.M., Wang L., Wang Y.C., Vassilieva E.V., et al. Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligand. Clin Vaccine Immunol 2012, 19:1119-1125.
7. Turley C.B., Rupp R.E., Johnson C., Taylor D.N., Wolfson J., Tussey L., et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4×M2e) in healthy adults. Vaccine 2011, 29:5145-5152.
8. Tompkins S.M., Zhao Z.S., Lo C.Y., Misplon J.A., Liu T., Ye Z., et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007, 13:426-435.
9. Song J.M., Van Rooijen N., Bozja J., Compans R.W., Kang S.M. Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci U S A 2011, 108:757-761.
10. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999, 5:1157-1163.
11. Huleatt J.W., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26:201-214.
12. Fu T.M., Grimm K.M., Citron M.P., Freed D.C., Fan J., Keller P.M., et al. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 2009, 27:1440-1447.
13. Ernst W.A., Kim H.J., Tumpey T.M., Jansen A.D., Tai W., Cramer D.V., et al. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 2006, 24:5158-5168.
14. Kim M.C., Song J.M., Kwon Y.M., Eunju O., Lee Y.J., Compans R.W., et al. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther 2013, 21:485-492.
15. Zou P., Liu W., Chen Y.H. The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection. Int Immunopharmacol 2005, 5:631-635.
16. Okuda K., Ihata A., Watabe S., Okada E., Yamakawa T., Hamajima K., et al. Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. Vaccine 2001, 19:3681-3691.
17. Mozdzanowska K., Feng J., Eid M., Kragol G., Cudic M., Otvos L., et al. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 2003, 21:2616-2626.
18. Liu W., Zou P., Chen Y.H. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Immunol Lett 2004, 93:131-136.
19. Fan J., Liang X., Horton M.S., Perry H.C., Citron M.P., Heidecker G.J., et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22:2993-3003.
20. Eliasson D.G., El Bakkouri K., Schon K., Ramne A., Festjens E., Lowenadler B., et al. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 2008, 26:1243-1252.
21. De Filette M., Martens W., Roose K., Deroo T., Vervalle F., Bentahir M., et al. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem 2008, 283:11382-11387.
22. Chen Z., Yoshikawa T., Kadowaki S., Hagiwara Y., Matsuo K., Asanuma H., et al. Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein. J Gen Virol 1999, 80(Pt 10):2559-2564.
23. Misplon J.A., Lo C.Y., Gabbard J.D., Tompkins S.M., Epstein S.L. Genetic control of immune responses to influenza A matrix 2 protein (M2). Vaccine 2010, 28:5817-5827.
24. Scheifele D.W., Ward B.J., Dionne M., Vanderkooi O.G., Loeb M., Coleman B.L., et al. Compatibility of ASO3-adjuvanted H1N1pdm09 and seasonal trivalent influenza vaccines in adults: results of a randomized, controlled trial. Vaccine 2012, 30:4728-4732.
25. Beran J., Peeters M., Dewe W., Raupachova J., Hobzova L., Devaster J.M. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC Infect Dis 2013, 13:224.
26. Fiers W., De Filette M., El Bakkouri K., Schepens B., Roose K., Schotsaert M., et al. M2e-based universal influenza A vaccine. Vaccine 2009, 27:6280-6283.
27. Franco L.M., Bucasas K.L., Wells J.M., Nino D., Wang X., Zapata G.E., et al. Integrative genomic analysis of the human immune response to influenza vaccination. Elife 2013, 2:e00299.
28. Garcon N., Chomez P., Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007, 6:723-739.
29. Kim M.C., Lee J.S., Kwon Y.M., Eunju O., Lee Y.J., Choi J.G., et al. Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection. Antiviral Res 2013, 99:328-335.
30. Song J.M., Wang B.Z., Park K.M., Van Rooijen N., Quan F.S., Kim M.C., et al. Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One 2011, 6:e14538.
31. Quan F.S., Kim Y.C., Yoo D.G., Compans R.W., Prausnitz M.R., Kang S.M. Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PLoS One 2009, 4:e7152.
32. Jouvin-Marche E., Morgado M.G., Leguern C., Voegtle D., Bonhomme F., Cazenave P.A. The mouse Igh-1a and Igh-1b H chain constant regions are derived from two distinct isotypic genes. Immunogenetics 1989, 29:92-97.
33. Martin R.M., Brady J.L., Lew A.M. The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J Immunol Methods 1998, 212:187-192.
34. Song J.M., Hossain J., Yoo D.G., Lipatov A.S., Davis C.T., Quan F.S., et al. Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology 2010, 405:165-175.
35. Brown D.M., Lee S., Garcia-Hernandez Mde L., Swain S.L. Multifunctional CD4 cells expressing gamma interferon and perforin mediate protection against lethal influenza virus infection. J Virol 2012, 86:6792-6803.
36. Didierlaurent A.M., Morel S., Lockman L., Giannini S.L., Bisteau M., Carlsen H., et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009, 183:6186-6197.